Xoma reports Q3 EPS ($1.59), consensus (44c)

Reports Q3 revenue $7.197M, consensus $6.49M. “We continue to take a balanced approach to building a portfolio of sustainable cashflow streams by selectively acquiring royalty economics across the lifecycle of drug development,” stated Owen Hughes, Chief Executive Officer of XOMA (XOMA) Royalty. “The September approval of MIPLYFFA(TM), the first therapy approved for patients living with Niemann-Pick disease Type C, adds to our growing commercial royalty portfolio, while the recent transaction with Twist Bioscience further expands our early-stage portfolio, a key focus for us as we look to distribute risk across a diversified portfolio.”